Generics Top 5 Emerging Markets Industry Guide_2017

mli0159 MarketLine 28 February, 2017 124 pages

Select License

Report Description
Table of Contents
Related Reports

Summary

The Emerging 5 Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the emerging five generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

- These countries contributed $87.1 billion to the global generics industry in 2016, with a compound annual growth rate (CAGR) of 14% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $145.8 billion in 2021, with a CAGR of 10.8% over the 2016-21 period.

- Within the generics industry, China is the leading country among the top 5 emerging nations, with market revenues of $63.1 billion in 2016. This was followed by India and Mexico with a value of $13.3 and $6.3 billion, respectively.

- China is expected to lead the generics industry in the top five emerging nations, with a value of $104.9 billion in 2021, followed by India and Mexico with expected values of $25.8 and $10.1 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the emerging five generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging five generics market

- Leading company profiles reveal details of key generics market players’ emerging five operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the emerging five generics market with five year forecasts by both value and volume

- Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country

Reasons to buy

- What was the size of the emerging five generics market by value in 2016?

- What will be the size of the emerging five generics market in 2021?

- What factors are affecting the strength of competition in the emerging five generics market?

- How has the market performed over the last five years?

- Who are the top competitors in the emerging five generics market?

Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Top Emerging Countries Generics
Industry Outlook
Generics in South Africa
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables

1Table 1: Top 5 emerging countries generics industry, revenue ($bn), 2012-21
2Table 2: Top 5 emerging countries generics industry, revenue ($bn), 2012-16
3Table 3: Top 5 emerging countries generics industry forecast, revenue ($bn), 2016-21
4Table 4: South Africa generics market value: $ billion, 2012–16
5Table 5: South Africa generics market volume: % of total pharma volume, 2012–16
6Table 6: South Africa generics market geography segmentation: $ billion,2016
7Table 7: South Africa generics market value forecast: $ billion, 2016–21
8Table 8: South Africa generics market volume forecast: % of total pharma volume, 2016–21
9Table 9: South Africa size of population (million), 2012–16
10Table 10: South Africa gdp (constant 2005 prices, $ billion), 2012–16
11Table 11: South Africa gdp (current prices, $ billion), 2012–16
12Table 12: South Africa inflation, 2012–16
13Table 13: South Africa consumer price index (absolute), 2012–16
14Table 14: South Africa exchange rate, 2012–16
15Table 15: Brazil generics market value: $ billion, 2012–16
16Table 16: Brazil generics market volume: % of total pharma volume, 2012–16
17Table 17: Brazil generics market geography segmentation: $ billion,2016
18Table 18: Brazil generics market value forecast: $ billion, 2016–21
19Table 19: Brazil generics market volume forecast: % of total pharma volume, 2016–21
20Table 20: Brazil size of population (million), 2012–16
21Table 21: Brazil gdp (constant 2005 prices, $ billion), 2012–16
22Table 22: Brazil gdp (current prices, $ billion), 2012–16
23Table 23: Brazil inflation, 2012–16
24Table 24: Brazil consumer price index (absolute), 2012–16
25Table 25: Brazil exchange rate, 2012–16
26Table 26: China generics market value: $ billion, 2012–16
27Table 27: China generics market volume: % of total pharma volume, 2012–16
28Table 28: China generics market geography segmentation: $ billion,2016
29Table 29: China generics market value forecast: $ billion, 2016–21
30Table 30: China generics market volume forecast: % of total pharma volume, 2016–21
31Table 31: China size of population (million), 2012–16
32Table 32: China gdp (constant 2005 prices, $ billion), 2012–16
33Table 33: China gdp (current prices, $ billion), 2012–16
34Table 34: China inflation, 2012–16
35Table 35: China consumer price index (absolute), 2012–16
36Table 36: China exchange rate, 2012–16
37Table 37: India generics market value: $ billion, 2012–16
38Table 38: India generics market volume: % of total pharma volume, 2012–16
39Table 39: India generics market geography segmentation: $ billion,2016
40Table 40: India generics market value forecast: $ billion, 2016–21
41Table 41: India generics market volume forecast: % of total pharma volume, 2016–21
42Table 42: India size of population (million), 2012–16
43Table 43: India gdp (constant 2005 prices, $ billion), 2012–16
44Table 44: India gdp (current prices, $ billion), 2012–16
45Table 45: India inflation, 2012–16
46Table 46: India consumer price index (absolute), 2012–16
47Table 47: India exchange rate, 2012–16
48Table 48: Mexico generics market value: $ billion, 2012–16
49Table 49: Mexico generics market volume: % of total pharma volume, 2012–16
50Table 50: Mexico generics market geography segmentation: $ billion,2016
51Table 51: Mexico generics market value forecast: $ billion, 2016–21
52Table 52: Mexico generics market volume forecast: % of total pharma volume, 2016–21
53Table 53: Mexico size of population (million), 2012–16
54Table 54: Mexico gdp (constant 2005 prices, $ billion), 2012–16
55Table 55: Mexico gdp (current prices, $ billion), 2012–16
56Table 56: Mexico inflation, 2012–16
57Table 57: Mexico consumer price index (absolute), 2012–16
58Table 58: Mexico exchange rate, 2012–16
59Table 59: Adcock Ingram Holdings Limited: key facts
60Table 60: Adcock Ingram Holdings Limited: key financials ($)
61Table 61: Adcock Ingram Holdings Limited: key financials (ZAR)
62Table 62: Adcock Ingram Holdings Limited: key financial ratios
63Table 63: Aspen Pharmacare Holdings Ltd: key facts
64Table 64: Aspen Pharmacare Holdings Ltd: key financials ($)
65Table 65: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
66Table 66: Aspen Pharmacare Holdings Ltd: key financial ratios
67Table 67: O Ache Laboratorios Farmaceuticos S.A.: key facts
68Table 68: EMS Sigma Pharma: key facts
69Table 69: Eurofarma Laboratórios S.A.: key facts
70Table 70: Sanofi SA: key facts
71Table 71: Sanofi SA: key financials ($)
72Table 72: Sanofi SA: key financials (€)
73Table 73: Sanofi SA: key financial ratios
74Table 74: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
75Table 75: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
76Table 76: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
77Table 77: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
78Table 78: Mylan Inc.: key facts
79Table 79: Mylan Inc.: key financials ($)
80Table 80: Mylan Inc.: key financial ratios
81Table 81: Sandoz International GmbH: key facts
82Table 82: Aurobindo Pharma Limited: key facts
83Table 83: Aurobindo Pharma Limited: key financials ($)
84Table 84: Aurobindo Pharma Limited: key financials (Rs.)
85Table 85: Aurobindo Pharma Limited: key financial ratios
86Table 86: Cipla Limited: key facts
87Table 87: Cipla Limited: key financials ($)
88Table 88: Cipla Limited: key financials (Rs.)
89Table 89: Cipla Limited: key financial ratios
90Table 90: Lupin Limited: key facts
91Table 91: Lupin Limited: key financials ($)
92Table 92: Lupin Limited: key financials (Rs.)
93Table 93: Lupin Limited: key financial ratios
94Table 94: Sun Pharmaceutical Industries Ltd.: key facts
95Table 95: Sun Pharmaceutical Industries Ltd.: key financials ($)
96Table 96: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
97Table 97: Sun Pharmaceutical Industries Ltd.: key financial ratios
98Table 98: Apotex, Inc.: key facts
99Table 99: Teva Pharmaceutical Industries Limited: key facts
100Table 100: Teva Pharmaceutical Industries Limited: key financials ($)
101Table 101: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures

1Figure 1: Top 5 emerging countries generics industry, revenue ($bn), 2012-21
2Figure 2: Top 5 emerging countries generics industry, revenue ($bn), 2012-16
3Figure 3: Top 5 emerging countries generics industry forecast, revenue ($bn), 2016-21
4Figure 4: South Africa generics market value: $ billion, 2012–16
5Figure 5: South Africa generics market volume: % of total pharma volume, 2012–16
6Figure 6: South Africa generics market geography segmentation: % share, by value,2016
7Figure 7: South Africa generics market value forecast: $ billion, 2016–21
8Figure 8: South Africa generics market volume forecast: % of total pharma volume, 2016–21
9Figure 9: Forces driving competition in the generics market in South Africa,2016
10Figure 10: Drivers of buyer power in the generics market in South Africa,2016
11Figure 11: Drivers of supplier power in the generics market in South Africa,2016
12Figure 12: Factors influencing the likelihood of new entrants in the generics market in South Africa,2016
13Figure 13: Factors influencing the threat of substitutes in the generics market in South Africa,2016
14Figure 14: Drivers of degree of rivalry in the generics market in South Africa,2016
15Figure 15: Brazil generics market value: $ billion, 2012–16
16Figure 16: Brazil generics market volume: % of total pharma volume, 2012–16
17Figure 17: Brazil generics market geography segmentation: % share, by value,2016
18Figure 18: Brazil generics market value forecast: $ billion, 2016–21
19Figure 19: Brazil generics market volume forecast: % of total pharma volume, 2016–21
20Figure 20: Forces driving competition in the generics market in Brazil,2016
21Figure 21: Drivers of buyer power in the generics market in Brazil,2016
22Figure 22: Drivers of supplier power in the generics market in Brazil,2016
23Figure 23: Factors influencing the likelihood of new entrants in the generics market in Brazil,2016
24Figure 24: Factors influencing the threat of substitutes in the generics market in Brazil,2016
25Figure 25: Drivers of degree of rivalry in the generics market in Brazil,2016
26Figure 26: China generics market value: $ billion, 2012–16
27Figure 27: China generics market volume: % of total pharma volume, 2012–16
28Figure 28: China generics market geography segmentation: % share, by value,2016
29Figure 29: China generics market value forecast: $ billion, 2016–21
30Figure 30: China generics market volume forecast: % of total pharma volume, 2016–21
31Figure 31: Forces driving competition in the generics market in China,2016
32Figure 32: Drivers of buyer power in the generics market in China,2016
33Figure 33: Drivers of supplier power in the generics market in China,2016
34Figure 34: Factors influencing the likelihood of new entrants in the generics market in China,2016
35Figure 35: Factors influencing the threat of substitutes in the generics market in China,2016
36Figure 36: Drivers of degree of rivalry in the generics market in China,2016
37Figure 37: India generics market value: $ billion, 2012–16
38Figure 38: India generics market volume: % of total pharma volume, 2012–16
39Figure 39: India generics market geography segmentation: % share, by value,2016
40Figure 40: India generics market value forecast: $ billion, 2016–21
41Figure 41: India generics market volume forecast: % of total pharma volume, 2016–21
42Figure 42: Forces driving competition in the generics market in India,2016
43Figure 43: Drivers of buyer power in the generics market in India,2016
44Figure 44: Drivers of supplier power in the generics market in India,2016
45Figure 45: Factors influencing the likelihood of new entrants in the generics market in India,2016
46Figure 46: Factors influencing the threat of substitutes in the generics market in India,2016
47Figure 47: Drivers of degree of rivalry in the generics market in India,2016
48Figure 48: Mexico generics market value: $ billion, 2012–16
49Figure 49: Mexico generics market volume: % of total pharma volume, 2012–16
50Figure 50: Mexico generics market geography segmentation: % share, by value,2016
51Figure 51: Mexico generics market value forecast: $ billion, 2016–21
52Figure 52: Mexico generics market volume forecast: % of total pharma volume, 2016–21
53Figure 53: Forces driving competition in the generics market in Mexico,2016
54Figure 54: Drivers of buyer power in the generics market in Mexico,2016
55Figure 55: Drivers of supplier power in the generics market in Mexico,2016
56Figure 56: Factors influencing the likelihood of new entrants in the generics market in Mexico,2016
57Figure 57: Factors influencing the threat of substitutes in the generics market in Mexico,2016
58Figure 58: Drivers of degree of rivalry in the generics market in Mexico,2016
59Figure 59: Adcock Ingram Holdings Limited: revenues & profitability
60Figure 60: Adcock Ingram Holdings Limited: assets & liabilities
61Figure 61: Aspen Pharmacare Holdings Ltd: revenues & profitability
62Figure 62: Aspen Pharmacare Holdings Ltd: assets & liabilities
63Figure 63: Sanofi SA: revenues & profitability
64Figure 64: Sanofi SA: assets & liabilities
65Figure 65: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
66Figure 66: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
67Figure 67: Mylan Inc.: revenues & profitability
68Figure 68: Mylan Inc.: assets & liabilities
69Figure 69: Aurobindo Pharma Limited: revenues & profitability
70Figure 70: Aurobindo Pharma Limited: assets & liabilities
71Figure 71: Cipla Limited: revenues & profitability
72Figure 72: Cipla Limited: assets & liabilities
73Figure 73: Lupin Limited: revenues & profitability
74Figure 74: Lupin Limited: assets & liabilities
75Figure 75: Sun Pharmaceutical Industries Ltd.: revenues & profitability
76Figure 76: Sun Pharmaceutical Industries Ltd.: assets & liabilities
77Figure 77: Teva Pharmaceutical Industries Limited: revenues & profitability
78Figure 78: Teva Pharmaceutical Industries Limited: assets & liabilities